ALADDIN Study Featured in The Economist

We are thrilled to share that The Economist recently featured the ALADDIN Study in their article, "Volunteers with Down’s Syndrome Could Help Find Alzheimer’s Drugs." This recognition highlights the increasing global interest in our groundbreaking research and underscores the critical importance of our mission: advancing Alzheimer’s therapeutics for all populations including individuals with Down syndrome.

The ALADDIN Study, led by researchers at the University of Southern California, is set to launch later this year. It focuses on evaluating the safety and efficacy of anti-amyloid immunotherapy, specifically donanemab, for individuals with Down syndrome. This demographic has been historically excluded from clinical trials, despite their increased risk of developing Alzheimer’s disease due to a genetic predisposition associated with an extra copy of chromosome 21.

Addressing a Critical Gap in Clinical Trials

Traditionally, people with Down syndrome have been left out of Alzheimer's drug trials, creating a significant gap in medical knowledge and treatment accessibility. As highlighted in The Economist, the inclusion of this group in clinical trials not only offers potential treatment benefits but could also advance our understanding of Alzheimer’s and contribute to broader prevention strategies.

Commitment to Equity and Inclusivity

Michael Rafii MD, PhD emphasizes the overarching goal of ensuring that all individuals, regardless of genetic conditions, have access to potentially life-changing treatments. “The ABATE and ALADDIN trials represent a significant step towards broader access to innovative therapies and improved outcomes for all populations," Rafii said.

As we approach the launch of the ALADDIN Study, we remain dedicated to our mission of creating a more inclusive research environment. We are hopeful that our work will not only benefit individuals with Down syndrome but also pave the way for more comprehensive Alzheimer's prevention strategies for the general population.

We invite you to stay connected with us on LinkedIn for updates on the study’s progress and to join us in advocating for a more inclusive future in clinical research.